Macrophage inhibitory cytokine-1: A review of its pleiotropic actions in cancer

Cancer Biomarkers

Volumn 11, Issue 5, 2012, Pages 183-190

  Khaled, Yazan S ^a,b,c,d   Elkord, Eyad ^a,b,e   Ammori, Basil J ^a,b,c,d  

^a UNIVERSITY OF SALFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^e UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

cancer; colorectal; Macrophage Inhibitory Cytokine 1; pancreatic; pleiotropic

Indexed keywords

CA 19-9 ANTIGEN; GROWTH DIFFERENTIATION FACTOR 15; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN P53;

BILIARY TRACT CANCER; BREAST CANCER; CANCER INVASION; CANCER STAGING; CLINICAL PRACTICE; COCHRANE LIBRARY; COLORECTAL CANCER; CONCENTRATION (PARAMETERS); EMBASE; GENETIC TRANSCRIPTION; HUMAN; MEDLINE; METASTASIS; PANCREAS CANCER; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; WEIGHT CONTROL; WEIGHT REDUCTION;

ANIMALS; COLORECTAL NEOPLASMS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 84871573868     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-00287     Document Type: Review

References (47)

1. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT: Macrophage inhibitory cytokine-1: A novel biomarker for p53 pathway activation. Mol Cancer Ther 2003, 2: 1023-1029.
2. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ, Bauskin AR, Kinzler KW, Vogelstein B, Breit SN: MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003, 9: 2642-2650. (Pubitemid 36842108)
3. Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-beta superfamily signaling. Faseb J 1999, 13: 2105-2124.
4. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl JMed 2000, 342: 1350-1358. (Pubitemid 30408720)
5. BootcovMR, BauskinAR,Valenzuela SM,MooreAG, Bansal M, He XY, Zhang HP, Donnellan M,Mahler S, Pryor K: MIC-1, a novelmacrophage inhibitory cytokine, is a divergentmember of the TGF-̂I2 superfamily. Proceedings of the National Academy of Sciences 1997, 94: 11514.
6. Ding Q, Mracek T, Gonzalez-Muniesa P, Kos K, Wilding J, Trayhurn P, Bing C: Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes. Endocrinology 2009, 150: 1688.
7. Ozkan H, Demirbaş S, Ibiş M, Akbal E, K̈okl̈u S: Diagnostic Validity of Serum Macrophage Inhibitor Cytokine and Tissue Polypeptide-Specific Antigen in Pancreatobiliary Diseases. Pancreatology 2011, 11: 295-300.
8. Yokoyama-Kobayashi M, Saeki M, Sekine S, Kato S: Human cDNA encoding a novel TGF-̂I2 superfamily protein highly expressed in placenta. Journal of Biochemistry 1997, 122: 622-626. (Pubitemid 27443241)
9. Hromas R, Hufford M, Sutton J, Xu D, Li Y, Lu L: PLAB, a novel placental bone morphogenetic protein. Biochim Biophys Acta 1997, 1354: 40-44. (Pubitemid 27479891)
10. Paralkar VM, Vail AL, Grasser WA, Brown TA, Xu H, Vukicevic S, Ke HZ, Qi H, Owen TA, Thompson DD: Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 1998, 273: 13760-13767. (Pubitemid 28268424)
11. Strelau J, Sullivan A, B̈ottner M, Lingor P, Falkenstein E, Suter-Crazzolara C, Galter D, Jaszai J, Krieglstein K, Unsicker K: Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo. The Journal of Neuroscience 2000, 20: 8597-8603.
12. Baek SJ, Kim KS, Nixon JB,Wilson LC, Eling TE: Cyclooxygenase inhibitors regulate the expression of a TGF-̂I2 superfamily member that has proapoptotic and antitumorigenic activities. Molecular Pharmacology 2001, 59: 901.
13. Mimeault M, Batra SK: Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. Journal of Cellular Physiology 2010, 224: 626-635.
14. Detmer K, Steele TA, Shoop MA, Dannawi H: Lineagerestricted expression of bone morphogenetic protein genes in human hematopoietic cell lines. Blood Cells Mol Dis 1999, 25: 310-323. (Pubitemid 30103951)
15. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, Hunter M, Breit SN: Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 2006, 66: 4983-4986. (Pubitemid 43852864)
16. Tan M, Wang Y, Guan K, Sun Y: PTGF-̂I2, a type ̂I2 transforming growth factor (TGF-̂I2) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-̂I2 signaling pathway. Proceedings of the National Academy of Sciences 2000, 97: 109.
17. Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ: Placental TGF-̂I2 is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. Journal of Biological Chemistry 2000.
18. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, et al.: Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003, 100: 3410-3415. (Pubitemid 36356597)
19. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, et al.: Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003, 63: 4648-4655. (Pubitemid 36951043)
20. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH: Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical Cancer Research 2004, 10: 2386-2392. (Pubitemid 38445697)
21. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AJ, Bentrem DJ, Talamonti MS, Bell RH: Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. Journal of Surgical Research 2007, 138: 163-169. (Pubitemid 46365718)
22. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA,Hunter M,Yeo C, ChanDW, Breit SN, Goggins M: Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006, 12: 442-446. (Pubitemid 43166133)
23. Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS, Murphy G, Laiyemo AO, Wang Z, Cross AJ, Schatzkin A: Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): A potential screening tool for the prevention of colon cancer? Cancer Epidemiology Biomarkers and Prevention, 2012.
24. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Hunter M, Liu T, Smith D,Kuffner T, Pankhurst GJ, et al.: The propeptide mediates formation of stromal stores of PROMIC-1: Role in determining prostate cancer outcome. Cancer Res 2005, 65: 2330-2336. (Pubitemid 40490143)
25. Schober A, Bottner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Breit SN, Unsicker K: Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 2001, 439: 32-45.
26. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J: Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 2010, 106: 1253-1264.
27. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patientswith primary breast cancer disease. Clin Cancer Res 2004, 10: 6418-6431. (Pubitemid 39346536)
28. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, Batra SK: Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 2010, 29: 1293-1302.
29. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, De Tribolet N: Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 2002, 21: 4212-4219. (Pubitemid 34753827)
30. Chen SJ, Karan D, Johansson SL, Lin FF, Zeckser J, Singh AP, Batra SK, Lin MF: Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptorpositive human prostate cancer cells. The Prostate 2007, 67: 557-571. (Pubitemid 46536948)
31. Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB, Johnston PG: Prostate-derived factor-A novel inhibitor of drug-induced cell death in colon cancer cells. Molecular Cancer Therapeutics 2009, 8: 2566-2574.
32. Kim KK, Lee JJ, Yang Y, You KH, Lee JH: Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008, 29: 704-712. (Pubitemid 351494157)
33. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKTmediated activation of estrogen receptor ̂I±. Journal of Biological Chemistry 2001, 276: 9817.
34. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, et al.: Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 2009, 69: 7696-7703.
35. Jatoi A:Weight loss in patients with advanced cancer: effects, causes, and potential management. Curr Opin Support Palliat Care 2008, 2: 45-48.
36. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, et al.: Tumorinduced anorexia and weight loss are mediated by the TGFbeta superfamily cytokine MIC-1. Nat Med 2007, 13: 1333-1340. (Pubitemid 350073601)
37. Skipworth RJE, Deans DAC, Tan BHL, Sangster K, Paterson-Brown S, Brown DA, Hunter M, Breit SN, Ross JA, Fearon KCH: Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. British Journal of Cancer 2010, 102: 665-672.
38. I. Dost́alov́a, T. Roub́cek, M. B́artlov́a, M. Mŕaz, Z. Lacinov́a, D. Haluźkov́a, P. Kav́alkov́a, M.Matoulek, M. Kasalicky and M. Haluźk, Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetesmellitus: the influence of very lowcalorie diet, European Journal of Endocrinology 161 (2009), 397-404.
39. Brown DA, Bauskin AR, FairlieWD, SmithMD, Liu T, Xu N, Breit SN: Antibody-based approach to high-volume genotyping for MIC-1 polymorphism. Biotechniques 2002, 33: 118-128.
40. Buckhaults P, Rago C, St Croix B, Romans KE, Saha S, Zhang L, Vogelstein B, Kinzler KW: Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Research 2001, 61: 6996.
41. Koprowski H, Steplewski Z,Mitchell K, Herlyn M, Herlyn D, Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell and Molecular Genetics 1979, 5: 957-971. (Pubitemid 10132218)
42. Goonetilleke K, Siriwardena A: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. European Journal of Surgical Oncology 2007, 33: 266-270. (Pubitemid 46488663)
43. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K, Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Research 2000, 60: 293.
44. Schrohl AS, Ẅurtz S, Kohn E, Banks RE, Nielsen HJ, Sweep FCGJ, Br̈unner N: Banking of biological fluids for studies of disease-associated protein biomarkers. Molecular & Cellular Proteomics 2008, 7: 2061-2066.
45. B̈unger S, Laubert T, Roblick UJ, Habermann JK: Serum biomarkers for improved diagnostic of pancreatic cancer: A current overview. Journal of Cancer Research and Clinical Oncology 2011: 1-15.
46. Rouy D, Ernens I, Jeanty C, Wagner DR: Plasma storage at-80 C does not protect matrix metalloproteinase-9 from degradation. Analytical Biochemistry 2005, 338: 294-298. (Pubitemid 40312594)
47. Pieragostino D, Petrucci F, Del Boccio P,Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C: Preanalytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. Journal of Proteomics 2010, 73: 579-592.